Figure 1.
Figure 1A: Progression free survival to pembrolizumab in patients with ≥ 90 day PFS vs patients with < 90 day PFS to ipilimumab, (237 days vs 125 days, P = 0.09).
Figure 1B: Overall survival to pembrolizumab in patients with ≥ 90 day PFS vs patients with < 90 day PFS to ipilimumab, (374 days vs 282 days, P = 0.06)